Match!
Therese Standal
Norwegian University of Science and Technology
ImmunologyMultiple myelomaBone marrowCancer researchMedicine
47Publications
16H-index
1,252Citations
What is this?
Publications 48
Newest
#1Magne Børset (NTNU: Norwegian University of Science and Technology)H-Index: 31
#2Anders Sundan (NTNU: Norwegian University of Science and Technology)H-Index: 32
Last. Therese Standal (NTNU: Norwegian University of Science and Technology)H-Index: 16
view all 4 authors...
Abstract The question of how myeloma cells cause destruction of skeletal tissue has interested scientists for many years, and knowledge in this field has developed in parallel with the understanding of physiological bone remodeling. The identification of bioactive proteins of the cytokine class during the last decades of the previous century and mapping of their role in the regulation of anabolic and catabolic processes in bone, led to a sequence of hypotheses about how the same peptides also co...
Source
#1Rui Yang (NTNU: Norwegian University of Science and Technology)H-Index: 1
#2Samah Elsaadi (NTNU: Norwegian University of Science and Technology)H-Index: 1
Last. Anders WaageH-Index: 50
view all 22 authors...
Background PD1/PDL1-directed therapies have been unsuccessful for multiple myeloma (MM), an incurable cancer of plasma cells in the bone marrow (BM). Therefore, other immune checkpoints such as extracellular adenosine and its immunosuppressive receptor should be considered. CD39 and CD73 convert extracellular ATP to adenosine, which inhibits T-cell effector functions via the adenosine receptor A2A (A2AR). We set out to investigate whether blocking the adenosine pathway could be a therapy for MM....
Source
#1Marita Westhrin (NTNU: Norwegian University of Science and Technology)H-Index: 5
#2Toril Holien (NTNU: Norwegian University of Science and Technology)H-Index: 15
Last. Therese Standal (NTNU: Norwegian University of Science and Technology)H-Index: 16
view all 16 authors...
Multiple myeloma is characterized by accumulation of malignant plasma cells in the bone marrow. Most patients suffer from an osteolytic bone disease, caused by increased bone degradation and reduced bone formation. Bone morphogenetic protein 4 (BMP4) is important for both pre- and postnatal bone formation and induces growth arrest and apoptosis of myeloma cells. BMP4-treatment of myeloma patients could have the potential to reduce tumor growth and restore bone formation. We therefore explored BM...
Source
#1Marita Westhrin (NTNU: Norwegian University of Science and Technology)H-Index: 5
#2Vlado Kovcic (NTNU: Norwegian University of Science and Technology)
Last. Therese Standal (NTNU: Norwegian University of Science and Technology)H-Index: 16
view all 10 authors...
Source
Source
#1Zejian Zhang (LUMC: Leiden University Medical Center)H-Index: 1
#2Marita Westhrin (NTNU: Norwegian University of Science and Technology)H-Index: 5
Last. Stephanie Holst (LUMC: Leiden University Medical Center)H-Index: 9
view all 6 authors...
Abstract Background Multiple myeloma is characterized by clonal proliferation of malignant plasma cells in the bone marrow that produce monoclonal immunoglobulins. N-glycosylation changes of these monoclonal immunoglobulins have been reported in multiple myeloma, but previous studies only detected limited serum N-glycan features. Methods Here, a more detailed study of the human serum N-glycome of 91 multiple myeloma patients and 51 controls was performed. We additionally analyzed sequential samp...
2 CitationsSource
#1Marita Westhrin (NTNU: Norwegian University of Science and Technology)H-Index: 5
#2Toril Holien (NTNU: Norwegian University of Science and Technology)H-Index: 15
Last. Therese Standal (VUmc: VU University Medical Center)H-Index: 16
view all 16 authors...
Multiple myeloma is characterized by accumulation of malignant plasma cells in the bone marrow. Most patients suffer from an osteolytic bone disease, caused by increased bone degradation and reduced bone formation. Bone morphogenetic protein 4 (BMP4) is important for both pre- and postnatal bone formation and induces growth arrest and apoptosis of myeloma cells. BMP4-treatment of myeloma patients could have the potential to reduce tumor growth and restore bone formation. We therefore explored BM...
Source
#1Toril Holien (NTNU: Norwegian University of Science and Technology)H-Index: 15
#2Marita Westhrin (NTNU: Norwegian University of Science and Technology)H-Index: 5
Last. Therese Standal (NTNU: Norwegian University of Science and Technology)H-Index: 16
view all 15 authors...
1 CitationsSource
#1Anne-Marit SponaasH-Index: 6
#2Rui YangH-Index: 1
Last. Anders SundanH-Index: 32
view all 10 authors...
// Anne-Marit Sponaas 1 , Rui Yang 1 , Even Holth Rustad 1 , Therese Standal 1, 2 , Aud Solvang Thoresen 5 , Camilla Dao Vo 5 , Anders Waage 1, 3 , Tobias S. Slordahl 1, 3 , Magne Borset 1, 4 and Anders Sundan 1, 2 1 Department of Clinical and Molecular Medicine, Myeloma Research Center, Norwegian University of Science and Technology, Trondheim, Norway 2 Centre of Molecular Inflammation Research, Centre of Molecular Immune Regulation, Norwegian University of Science and Technology, Trondheim, No...
4 CitationsSource
#1Marita Westhrin (NTNU: Norwegian University of Science and Technology)H-Index: 5
#2Siv Helen Moen (NTNU: Norwegian University of Science and Technology)H-Index: 7
Last. Therese Standal (NTNU: Norwegian University of Science and Technology)H-Index: 16
view all 9 authors...
Chemerin is a recently discovered adipokine shown to be involved in both inflammatory and metabolic processes. Here, we demonstrate that chemerin serum levels are elevated in patients with multiple myeloma and that it increases with disease progression. We found that chemerin is expressed by stromal cells and preadipocytes, whereas its receptor CCRL2 is expressed by primary myeloma cells, suggesting a paracrine signaling loop between bone marrow stromal cells/adipocytes and myeloma cells. This i...
1 CitationsSource
12345